On Sept. 17, 2020, Eli Lilly and Amgen announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly’s potential COVID-19 therapies.

Lilly was studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination.